PGY-2 Oncology Residency Pharmacy


PGY2 pharmacy residency programs build on Doctor of Pharmacy (Pharm.D.) education and PGY1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY2 residencies provide residents with opportunities to function independently as practitioners by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings. Residents who successfully complete an accredited PGY2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.

Additional Program Description

A resident who successfully completes this PGY2 Oncology Pharmacy Residency Program should possess knowledge and competencies that enable attainment of board certification in the practice area (i.e. BCOP) and exhibit the skills and attitudes to successfully enter clinical practice as a pharmacy specialist in the inpatient and or outpatient setting, or assume a faculty role within a college of pharmacy.

Program Design

The PGY2 Oncology Pharmacy Residency at MUSC is a one-year post-graduate training program designed to develop essential knowledge and skills for contemporary health-system pharmacy practice at a major academic medical center, community-based hospital, or in academia. The residency program provides the flexibility to adapt to the resident's specific learning needs and goals. The training is provided through concentrated clinical and longitudinal experiences as listed below:

Required Rotations:

Orientation -- 1 month

Project (December) -- 1 month

Inpatient Malignant Hematology -- 1 month

Outpatient Malignant Hematology -- 1 month

BMT/Cellular Therapy Clinic -- 1 month

Breast Oncology Clinic* -- 1 month

Thoracic Oncology Clinic* -- 1 month

Gynecologic Oncology Clinic* -- 1 month

Gastrointestinal Oncology Clinic* -- 1 month

Genitourinary Oncology Clinic* -- 1 month

Palliative Care Clinic --2 weeks

Skin Cancer Clinic --2 weeks

*= any of the above rotations can be selected as a longitudinal clinic experience Duration

Elective Rotations (choice of 1-2 with repeat experiences from required rotations allowed):

Neurologic Oncology Clinic -- 1 month

Infectious Diseases -- 1 month

Pediatric Oncology -- 1 month

Outpatient Specialty Pharmacy Duration -- 1 month

Clinical Staffing Experience

Residents will gain oncology staffing experiences through inpatient staffing on the oncology unit at Ashley River Tower one weekend per month (10-hour shifts), and outpatient staffing at the Hollings Cancer Center’s infusion center 2 days per month (8-hour shifts). Inpatient staffing consists of checking chemotherapy orders, discharge counseling, verifying orders, and cross-covering orders from other units as required by the shift. Outpatient infusion staffing consists of verifying chemotherapy orders, checking preparation of chemotherapy, and exposure to compounding chemotherapy through closed system transfer devices. Residents are expected to communicate with nursing staff, clinic/hospital staff, and clinical specialist pharmacy staff to answer questions and ensure safe preparation, dispensing and administration of chemotherapy.

Longitudinal Experiences

  • Major Research Project: a project selected by the resident in July after they have been presented with all options by the specialist pharmacists. This will be an ongoing project throughout the residency year, and will be presented at HOPA or other oncology meeting, in the spring. A manuscript will be written by the end of the residency year, with the intent on submitting for publication. Completion of the research certificate program through the MUSC College of Pharmacy is highly encouraged.
  • Medication Use Evaluation: a project selected by preceptors, with the residents interests in mind, that will greatly benefit patients and staff at MUSC. The timeline/completion of this project will be based on the individual project needs.
  • Topic Discussions: This longitudinal experience is more heavily focused during the first quarter of the residency year to prepare residents for staffing and rotations. Throughout the remainder of the year, specific disease-state/supportive care topics will be addressed with direct patient care activities or individual topic discussions with the preceptor. For any ASHP-required disease-states or topics not specifically covered during a monthly rotation, these will be addressed during the remaining group/longitudinal topic discussions. An outline of all disease-states and supportive care topics to be covered throughout the year will be given to the residents during their orientation (July).
  • Journal Club: Journal club is held monthly, and the PGY2 resident is expected to present/lead at least 2 journal club discussions throughout the year, and complete an evaluation for all journal club presentations they attend. Additional learners on rotation within Hollings Cancer Center, including other PGY2 residents, PGY1 residents, and students will also be expected to participate in this activity.
  • Case Presentations: Residents will choose and present 2 patient cases throughout the year. These should be rare or interesting cases they have encountered on rotation.
  • Capstone Solid Tumor Clinic: To be selected by the resident from the list above of solid tumor rotations. As a longitudinal rotation, beginning in September or October, the resident will go to that clinic 1 day per week, and this will continue for ~6 months (quarter 2 and quarter 3). During quarter 4, the resident can change to any clinic they choose in preparation for their future employment.
  • Investigational Drug Services: IDS experience will be provided in several different learning opportunities. During orientation, the resident will spend time learning trial protocols, where to find information and how to dispense investigational drugs for trial patients. Throughout the year, the resident will review trial protocols for appropriate medication use, counsel patients, monitor for adverse events, and perform any other trial-related tasks assigned by the preceptor. During outpatient infusion staffing, the resident will be encouraged to verify and participate in the dispensing of investigational drugs that occur during their shift. The resident will also participate in topic discussions focused on IDS, and they will assist with preparing a template for the EPIC/Beacon treatment plan build for a new trial opening at MUSC. They may also be asked to participate in the protocol validation, site initiation visit, and other learning opportunities as available in a longitudinal fashion.
  • Oncology Management: This experience will include a monthly meeting with a member of the management team to review a list of pertinent and relevant topics to help prepare the resident for BCOP and managerial tasks they will likely participate in throughout their practice. Residents are encouraged to suggest additional topics/questions for the management team that can be added and scheduled as needed. Topics to be covered will include interviewing, CV review, employment benefits, and other pertinent information to help prepare residents for future employment interviews.

Precepting/Teaching Experiences

  • Seminar: Each resident will complete a 1-hour seminar presentation during the year. This will be presented to the pharmacy department as an ACPE-accredited continuing education activity.
  • Precepting: Each resident will precept at least 1 student on rotation each year. If desired, more experiences can be offered based on availability.
  • Didactic Teaching: Residents will teach at least 1 lecture to 3rd year pharmacy students at MUSC College of Pharmacy in the Spring Semester. Other opportunities may be offered based on desire and availability.
  • APP: See general landing page for more information. This is an optional activity but highly encouraged for each resident to complete.

Core Preceptors

Jennifer MacDonald, PharmD, BCOP
Clinical Oncology Specialist, Gynecologic Oncology

Anastasia Graham, PharmD, BCOP
Clinical Oncology Specialist, Neurologic Oncology

Jagoda Misniakiewicz, PharmD
Clinical Oncology Specialist, Gastrointestinal Oncology

Kasey Jackson, PharmD, BCOP
Clinical Oncology Specialist, Breast Oncology

Serry Vogt, PharmD, BCOP
Clinical Oncology Specialist, Genitourinary and Head/Neck Oncology

Andy Maldonado, PharmD, BCOP
Clinical Oncology Specialist, Faculty MUSC College of Pharmacy, Melanoma and Skin Cancers

Christina Hoppe, PharmD, BCOP
Clinical Oncology Specialist, Thoracic Oncology

James Davis, PharmD, BCOP
Clinical Oncology Specialist, Malignant Hematology (Outpatient)

Deidra Smith, PharmD
Clinical Oncology Specialist, Malignant Hematology (Outpatient)

Kelly Gaffney, PharmD, BCOP
Clinical Oncology Specialist, BMT/Cellular Therapy and Malignant Hematology (Inpatient)

Kathy Edwards, PharmD, BCPS, BCOP, FHOPA
Clinical Oncology Specialist, BMT/Cellular Therapy (Outpatient)

Mary McGann, PharmD, BCOP
Clinical Oncology Specialist, BMT/Cellular Therapy (Outpatient)

Julie Heh, PharmD, BCPS, BCPPS
Clinical Pediatric Specialist, Pediatric Oncology

Jennifer Carter, PharmD, BCPS
Director, MUSC Specialty Pharmacy

Leslie Person, PharmD, BCPS
Clinical Pharmacist, Inpatient Oncology

Krutika Hornback, PharmD, BCPS, BCIDP
Clinical Infectious Diseases Specialist

Current Residents

PGY2 Oncology Pharmacy Residents

Requirements for Program

Completion See Appendix A in our Residency Manual